AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33200303 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (S-1 plus cisplatin) followed by D2 gastrectomy plus adjuvant chemotherapy with S-1 (Arm B)
Number of subjects: 316
Study 33200303 — intervention group
Group type: COMPARATOR
Intervention: D2 surgery followed by adjuvant chemotherapy with S-1 (Arm A)
Number of subjects: 316
Study 33042004 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic Diet (VLCKD)
Number of subjects: 39
Study 33042004 — intervention group
Group type: COMPARATOR
Intervention: Standard Low-Calorie Diet (LC)
Number of subjects: 39
Study 33811761 — intervention group
Group type: EXPERIMENTAL
Intervention: Velusetrag 30 mg
Number of subjects: 34
Study 33811761 — intervention group
Group type: COMPARATOR
Intervention: Velusetrag 5 mg
Number of subjects: 34
Study 33811761 — intervention group
Group type: COMPARATOR
Intervention: Velusetrag 15 mg
Number of subjects: 34
Study 33811761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 34252122 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing a narrative text about a fictional person
Number of subjects: 0
Study 34252122 — intervention group
Group type: COMPARATOR
Intervention: Writing about an unrelated topic
Number of subjects: 0
Study 32473020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate 400mg twice daily on Day 1, then 400mg once daily from Day 2 to Day 10
Number of subjects: 0
Study 33527859 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE-Life walking intervention
Number of subjects: 16
Study 33947726 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial support (PicPecc)
Number of subjects: 0
Study 93204632 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (3 million units three times weekly)
Number of subjects: 48
Study 93204632 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (3 million units three times weekly) after prednisolone withdrawal
Number of subjects: 48
Study 93204632 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ALT normalization
Number of subjects: 48
Study 93204632 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prednisolone pretreatment
Number of subjects: 48
Study 93204632 — intervention group
Group type: COMPARATOR
Intervention: Patients without prednisolone pretreatment
Number of subjects: 48
Study 35438151 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicagrel 20/5 mg (LD/MD)
Number of subjects: 279
Study 35438151 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicagrel 24/6 mg
Number of subjects: 279
Study 35438151 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicagrel 30/7.5 mg
Number of subjects: 279
Study 35438151 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300/75 mg
Number of subjects: 279
Study 34285350 — intervention group
Group type: EXPERIMENTAL
Intervention: Decipher Biopsy testing
Number of subjects: 855
Study 32035053 — intervention group
Group type: EXPERIMENTAL
Intervention: CaniLeishÂ® vaccine, n = 85
Number of subjects: 168
Study 35830649 — intervention group
Group type: EXPERIMENTAL
Intervention: A+AVD
Number of subjects: 1334
Study 35830649 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 1334
Study 34223754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic drainage kinesis‐taping
Number of subjects: 33
Study 34223754 — intervention group
Group type: COMPARATOR
Intervention: Complex treatment including lymphatic drainage kinesis‐taping and low-frequency pulse magnetic therapy
Number of subjects: 33
Study 32279471 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard modified Epley maneuver (mEpley)
Number of subjects: 41
Study 32279471 — intervention group
Group type: COMPARATOR
Intervention: Modified Epley maneuver with a pillow under the shoulders (mEpley‐PS)
Number of subjects: 41
Study 34259826 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily for 12 weeks
Number of subjects: 50
Study 34259826 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 50
Study 33745865 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (120 mg twice daily) during chemoradiotherapy (CRT)
Number of subjects: 52
Study 33745865 — intervention group
Group type: COMPARATOR
Intervention: Placebo during chemoradiotherapy (CRT)
Number of subjects: 52
Study 35092305 — intervention group
Group type: EXPERIMENTAL
Intervention: KY1005 (0.006, 0.018, 0.05, 0.15, 0.45, 1.35, 4, or 12 mg/kg)
Number of subjects: 64
Study 35092305 — intervention group
Group type: EXPERIMENTAL
Intervention: KY1005 (0.45 mg/kg and above)
Number of subjects: 64
Study 35092305 — intervention group
Group type: EXPERIMENTAL
Intervention: KY1005
Number of subjects: 64
Study 35092305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 33833182 — intervention group
Group type: COMPARATOR
Intervention: Private aesthetic surgeons
Number of subjects: 145
Study 33833182 — intervention group
Group type: COMPARATOR
Intervention: Private ASAPS surgeons (n = 126)
Number of subjects: 145
Study 35615229 — intervention group
Group type: EXPERIMENTAL
Intervention: ProximaTM point of care device
Number of subjects: 20
Study 35615229 — intervention group
Group type: COMPARATOR
Intervention: Standard ABG sampling system
Number of subjects: 20
Study 32741143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Methotrexate (target dose 15-20 mg/week)
Number of subjects: 4786
Study 32741143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4786
Study 35923827 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline (Rischiaril® Forte, 1,000 mg of citicoline sodium salt)
Number of subjects: 30
Study 35923827 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group - CG)
Number of subjects: 30
Study 33373492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 28
Study 33373492 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 28
Study 35020019 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat and Extend (T&E) regimen
Number of subjects: 124
Study 35020019 — intervention group
Group type: COMPARATOR
Intervention: Pro Re Nata (PRN) regimen
Number of subjects: 124
Study 33819066 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide orodispersible tablets
Number of subjects: 0
Study 33819066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34351504 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM imitation + toothpaste with SA8% (G2)
Number of subjects: 80
Study 34351504 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM + toothpaste with SA8% (G4)
Number of subjects: 80
Study 34351504 — intervention group
Group type: COMPARATOR
Intervention: PBM imitation + toothpaste with no active ingredient (G1)
Number of subjects: 80
Study 34351504 — intervention group
Group type: COMPARATOR
Intervention: PBM + toothpaste without the active ingredient (G3)
Number of subjects: 80
Study 33529620 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 33529620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32048131 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) intravenously for 72 hours (150 mg/kg/h for 1 hour, followed by 12.5 mg/kg/h for 4 hours, followed by 6.25 mg/kg for 67 hours)
Number of subjects: 214
Study 32048131 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) intravenously for 72 hours
Number of subjects: 214
Study 32048131 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 214
Study 33587403 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (700 mg) + Lisdexamfetamine (50 mg)
Number of subjects: 36
Study 33587403 — intervention group
Group type: COMPARATOR
Intervention: Lisdexamfetamine (50 mg)
Number of subjects: 36
Study 33587403 — intervention group
Group type: COMPARATOR
Intervention: Viloxazine extended-release (700 mg)
Number of subjects: 36
Study 35063243 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg per day for 24 weeks)
Number of subjects: 60
Study 35063243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch for 24 weeks)
Number of subjects: 60
Study 32998018 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional online management
Number of subjects: 309
Study 32998018 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical prenatal care
Number of subjects: 309
Study 35987546 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based Behavioral Activation (BA) intervention, eight weekly individual sessions
Number of subjects: 71
Study 35987546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 71
Study 32097450 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye diet (± SDG supplements)
Number of subjects: 40
Study 35899230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mustard (MU)
Number of subjects: 18
Study 35899230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (GI)
Number of subjects: 18
Study 35899230 — intervention group
Group type: COMPARATOR
Intervention: Warm water (WA)
Number of subjects: 18
Study 32033227 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (evidence-based brochure, phone counseling, mailed reminders, and communications with primary care providers)
Number of subjects: 178
Study 32033227 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity intervention (brochure only)
Number of subjects: 178
Study 32033227 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention
Number of subjects: 178
Study 32033227 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity intervention
Number of subjects: 178
Study 34154965 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of black pepper essential oil
Number of subjects: 60
Study 34154965 — intervention group
Group type: COMPARATOR
Intervention: No extra interventions (Control group)
Number of subjects: 60
Study 33633233 — intervention group
Group type: EXPERIMENTAL
Intervention: Catvira (epigallocatechingallate + sofosbuvir + ribavirin)
Number of subjects: 80
Study 33633233 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir + ribavirin
Number of subjects: 80
Study 32889836 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (FFX)
Number of subjects: 413
Study 32889836 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine plus nab-paclitaxel (GNP)
Number of subjects: 413
Study 32889836 — intervention group
Group type: EXPERIMENTAL
Intervention: FFX-GNP crossover
Number of subjects: 413
Study 32889836 — intervention group
Group type: COMPARATOR
Intervention: GNP-FFX crossover
Number of subjects: 413
Study 35529283 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acid-etch sealant (Group 1)
Number of subjects: 35
Study 35529283 — intervention group
Group type: COMPARATOR
Intervention: Self-etch sealant (Group 2)
Number of subjects: 35
Study 33350893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspherical polyvinyl alcohol (PVA) particles (355‐550 μm)
Number of subjects: 54
Study 33350893 — intervention group
Group type: COMPARATOR
Intervention: Tris‐acryl gelatin microspheres (TAGM) (500‐700 μm)
Number of subjects: 54
Study 36273210 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises (group 1)
Number of subjects: 105
Study 36273210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of strengthening exercises and functional swallowing therapy (group 2)
Number of subjects: 105
Study 36273210 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation added to the combination of strengthening exercises and functional swallowing therapy (group 3)
Number of subjects: 105
Study 33205809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag (single IV dose at peak concentrations of the anticoagulant)
Number of subjects: 2
Study 33205809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag (given after the bleeding injury)
Number of subjects: 2
Study 32151538 — intervention group
Group type: EXPERIMENTAL
Intervention: NELCIN-B3 protocol for managing early-detected lung nodules
Number of subjects: 10000
Study 32151538 — intervention group
Group type: COMPARATOR
Intervention: Routine CT protocol for managing early-detected lung nodules
Number of subjects: 10000
Study 32151538 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative measurement of CT imaging biomarkers
Number of subjects: 10000
Study 32197070 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 12
Study 32197070 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 12
Study 32197070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35859298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-silymarin (SinaLive soft gel, 70 mg silymarin as nanomicelles, three times daily for two weeks)
Number of subjects: 50
Study 35859298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily for two weeks)
Number of subjects: 50
Study 34724938 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 2084
Study 34724938 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 2084
Study 34724938 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Tree model
Number of subjects: 2084
Study 34724938 — intervention group
Group type: COMPARATOR
Intervention: GRACE risk variable set model
Number of subjects: 2084
Study 34724938 — intervention group
Group type: EXPERIMENTAL
Intervention: RBBB (Right Bundle Branch Block)
Number of subjects: 2084
Study 34724938 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 2 ventricular walls motion abnormal
Number of subjects: 2084
Study 34724938 — intervention group
Group type: EXPERIMENTAL
Intervention: Right coronary artery occlusion
Number of subjects: 2084
Study 35543652 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (SGA)
Number of subjects: 11
Study 35543652 — intervention group
Group type: COMPARATOR
Intervention: Bag-mask ventilation (BMV)
Number of subjects: 11
Study 34166263 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (self‐weaning from sling and performance of active range of motion as tolerated during first 6 weeks)
Number of subjects: 101
Study 34166263 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 101
Study 34166263 — intervention group
Group type: COMPARATOR
Intervention: Immobilization (splinting for 6 weeks with no active range of motion)
Number of subjects: 101
Study 34166263 — intervention group
Group type: COMPARATOR
Intervention: Early mobilization and Immobilization
Number of subjects: 101
Study 35534091 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita 500 (liquid formulation)
Number of subjects: 0
Study 35534091 — intervention group
Group type: COMPARATOR
Intervention: Tablets
Number of subjects: 0
Study 35534091 — intervention group
Group type: COMPARATOR
Intervention: Capsules
Number of subjects: 0
Study 34342299 — intervention group
Group type: EXPERIMENTAL
Intervention: TREPP
Number of subjects: 0
Study 34342299 — intervention group
Group type: COMPARATOR
Intervention: TIPP
Number of subjects: 0
Study 34342299 — intervention group
Group type: EXPERIMENTAL
Intervention: TREPP (corrected for learning curve)
Number of subjects: 0
Study 34342299 — intervention group
Group type: COMPARATOR
Intervention: TIPP (corrected for learning curve)
Number of subjects: 0
Study 36490244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health coaching via a mobile app for 3 months after discharge.
Number of subjects: 180
Study 36490244 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face counseling with a clinical dietitian at 1 and 3 months postoperatively.
Number of subjects: 180
Study 35519929 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet mask
Number of subjects: 60
Study 35519929 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 60
Study 32804621 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐PROACTIF intervention (Integrated PRimary care and Occupational therapy for Aging and Chronic disease Treatment to preserve Independence and Functioning)
Number of subjects: 18
Study 32804621 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐PROACTIF intervention
Number of subjects: 18
Study 32804621 — intervention group
Group type: COMPARATOR
Intervention: Complex care management (control)
Number of subjects: 18
Study 35377160 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Number of subjects: 1446
Study 35377160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1446
Study 33488071 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/G DPI (100/6/10µg via DPI, two inhalations twice daily for four weeks)
Number of subjects: 366
Study 33488071 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/G pMDI (100/6/10µg via pMDI, two inhalations twice daily for four weeks)
Number of subjects: 366
Study 33488071 — intervention group
Group type: COMPARATOR
Intervention: BDP/FF (100/6µg via pMDI, two inhalations twice daily for four weeks)
Number of subjects: 366
Study 32394059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric surgical RCTs
Number of subjects: 0
Study 34528079 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab (300 or 150 mg weekly, then 4-weekly thereafter)
Number of subjects: 166
Study 34528079 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 166
Study 34528079 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 166
Study 33408531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose complex (ISC)
Number of subjects: 40
Study 33408531 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight iron dextran (LMWID)
Number of subjects: 40
Study 34964475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia ablation
Number of subjects: 259
Study 34964475 — intervention group
Group type: COMPARATOR
Intervention: Escalated antiarrhythmic drug therapy
Number of subjects: 259
Study 33169168 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth with stigmatizing attitudes towards patients with podoconiosis
Number of subjects: 336
Study 33169168 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate knowledge about gene-environment influences
Number of subjects: 336
Study 33169168 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejection of infectious causes of podoconiosis
Number of subjects: 336
Study 35846977 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application education (n=30)
Number of subjects: 60
Study 35846977 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical education (n=30)
Number of subjects: 60
Study 32564630 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (8 sessions)
Number of subjects: 24
Study 32564630 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 24
Study 36397018 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (60 min per session, 3 sessions per week for 24 weeks)
Number of subjects: 72
Study 36397018 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity (control group)
Number of subjects: 72
Study 35082913 — intervention group
Group type: EXPERIMENTAL
Intervention: DSA group
Number of subjects: 60
Study 35082913 — intervention group
Group type: COMPARATOR
Intervention: CTA group
Number of subjects: 60
Study 33020083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol plus nimodipine
Number of subjects: 0
Study 33020083 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine alone
Number of subjects: 0
Study 35313935 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based intervention (HAPPYTEEN) based on Transtheoretical Model (TTM) and Cognitive-Behavioral Therapy (CBT) delivered over 8 sessions for 2 months
Number of subjects: 206
Study 35313935 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene intervention delivered over 8 sessions for 2 months via the app
Number of subjects: 206
Study 33991702 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy of sacral torsion
Number of subjects: 64
Study 33991702 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release
Number of subjects: 64
Study 32208117 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) transfersomal gel
Number of subjects: 30
Study 32208117 — intervention group
Group type: COMPARATOR
Intervention: Free MB gel
Number of subjects: 30
Study 35315874 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (n=565)
Number of subjects: 1557
Study 35315874 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor (n=455)
Number of subjects: 1557
Study 35315874 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet therapy (control; n=529)
Number of subjects: 1557
Study 32439603 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginary eating of 30 colorful button-shaped chocolates (M&Ms)
Number of subjects: 86
Study 32439603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorting of 30 M&Ms by color
Number of subjects: 86
Study 32439603 — intervention group
Group type: COMPARATOR
Intervention: Sorting of 30 marbles by color
Number of subjects: 86
Study 35202073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program including three modules focusing on improving pharmacists’ communication skills to proactively offer naloxone.
Number of subjects: 0
Study 35202073 — intervention group
Group type: COMPARATOR
Intervention: Control group completing a reading assignment on the naloxone consensus guidelines.
Number of subjects: 0
Study 32556176 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod cream followed by intradermal HBVv (IMQ + ID)
Number of subjects: 94
Study 32556176 — intervention group
Group type: COMPARATOR
Intervention: Topical aqueous cream (placebo) followed by intradermal HBVv (AQ + ID)
Number of subjects: 94
Study 32556176 — intervention group
Group type: COMPARATOR
Intervention: Topical aqueous cream followed by intramuscular HBVv (AQ + IM)
Number of subjects: 94
Study 32338720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled phototherapy (PT) regimen of 15 min/h or more
Number of subjects: 305
Study 32338720 — intervention group
Group type: COMPARATOR
Intervention: Continuous phototherapy (PT)
Number of subjects: 305